Aurinia Pharmaceuticals Inc.
Small molecule and biologic therapies for autoimmune diseases
- Sector
- Biotech
- Headquarters
- VICTORIA, A1
- Founded
- 2009
- Latest Form D
- $52M, Feb 2014
- Total capital
- $52M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $52M
- 1 Form D · last Feb 2014
- 152 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 19 pending · first 2017
- Rank in peer group#213 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$52M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Benjamin M. RovinskiDirectorNamed in SEC Form D filings
- Chris M. KimDirectorNamed in SEC Form D filings
- Daniel M. ParkDirectorNamed in SEC Form D filings
- Dennis M. BourgeaultExecutive OfficerNamed in SEC Form D filings
- Donald M. WyattDirectorNamed in SEC Form D filings
- Kurt von M. EmsterDirectorNamed in SEC Form D filings
Show all 10 people
- Michael M. MartinExecutive Officer, DirectorNamed in SEC Form D filings
- Peter M. WijngaardDirectorNamed in SEC Form D filings
- Richard M. GlickmanExecutive Officer, DirectorNamed in SEC Form D filings
- Stephen W. ZarubyExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 26- PendingProtocol For Treatment Of Lupus NephritisUSPTOApplication 19074311
- PendingB Cell Activating Factor (baff)-a Proliferation Inducing Ligand (april) Dual InhibitorsUSPTOApplication 18663461
- PendingProtocol To Minimize Calcineurin Inhibitor NephrotoxicityUSPTOApplication 18272337
Show all 26 patent records
- Protocol For Treatment Of Lupus NephritisJun 26, 2025 · Application 19074311Pending
- B Cell Activating Factor (baff)-a Proliferation Inducing Ligand (april) Dual InhibitorsFeb 6, 2025 · Application 18663461Pending
- Protocol To Minimize Calcineurin Inhibitor NephrotoxicityMar 7, 2024 · Application 18272337Pending
- Protocol To Minimize Calcineurin Inhibitor NephrotoxicityNov 30, 2023 · Application 18361775Pending
- Methods Of Treating Or Preventing Coronavirus InfectionJun 15, 2023 · Application 17923552Pending
- Protocol For Treatment Of Lupus NephritisApr 11, 2023 · US 11,622,991Granted
- Ophthalmic CompositionsNov 4, 2021 · Application 17228480Pending
- Ophthalmic CompositionsApr 13, 2021 · US 10,973,871Granted
- Cyclosporine Analogue Mixtures And Their Use As Immunomodulating AgentsSep 29, 2020 · US RE48,226Granted
- Cyclosporine Analogue Mixtures And Their Use As Immunomodulating AgentsNov 12, 2019 · US 10,472,394Granted
- Protocol For Treatment Of Lupus NephritisJul 25, 2019 · Application 16374701Pending
- Protocol For Treatment Of Lupus NephritisMay 14, 2019 · US 10,286,036Granted
- Ophthalmic CompositionsApr 23, 2019 · US 10,265,375Granted
- Cyclosporine Analogue Mixtures And Their Use As Immunomodulating AgentsSep 19, 2017 · US 9,765,119Granted
- Topical Drug Delivery System for Ophthalmic UseJul 23, 2015 · Application 14676993Pending
- Cyclosporine Analogue Mixtures And Their Use As Immunomodulating AgentsDec 18, 2014 · Application 14324146Pending
- Synthesis of Cyclosporin AnalogsSep 25, 2014 · Application 14217827Pending
- Cyclosporin Analog FormulationsSep 4, 2014 · Application 14201872Pending
- Deuterated Cyclosporine Analogs and Methods of Making the SameAug 21, 2014 · Application 14182231Pending
- Cyclosporine Analogue Mixtures And Their Use As Immunomodulating AgentsMay 22, 2014 · Application 14042226Pending
- Methods For Treating Lupus Nephritis With VoclosporinApplication 19487979Pending
- Methods For Treating Lupus Nephritis With VoclosporinApplication 63513690Pending
- Methods For Treating Lupus Nephritis With VoclosporinApplication 63505394Pending
- Protocol For Treatment Of Lupus NephritisApplication 62541612Pending
- Protocol For Treatment Of Lupus NephritisApplication 62505734Pending
- Methods And Uses Related To Administration Of VoclosporinApplication 19472580Pending
Related companies, and why
- Achelios Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Pulmatrix, Inc.Similar federal contract value in Biotech · null in contracts
- ImmunoVec, Inc.Similar federal contract value in Biotech · null in contracts
- Indi Molecular, Inc.Similar federal contract value in Biotech · null in contracts
- Annovis Bio, Inc.Similar federal contract value in Biotech · null in contracts
- NEXILICO, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .